| Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock |
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology. |
zacks.com |
2025-05-15 14:45:44 |
Czytaj oryginał (ang.) |
| Should You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip? |
Artificial intelligence (AI) has taken over Wall Street. The leaders in this rapidly growing field are attracting significant attention. |
fool.com |
2025-05-12 08:18:00 |
Czytaj oryginał (ang.) |
| 2 Top Artificial Intelligence (AI) Stocks to Buy Right Now |
The artificial intelligence (AI) revolution is reshaping our world at an unprecedented pace. As AI technology evolves, it's set to fundamentally transform countless industries through enhanced automation, operational efficiency, and dramatic improvements in workforce productivity. |
fool.com |
2025-05-11 12:00:00 |
Czytaj oryginał (ang.) |
| Why Recursion Pharmaceuticals Stock Plummeted 24% This Week |
Shares of Recursion Pharmaceuticals (RXRX -1.48%) fell this week. The stock lost 24% as of market close on Friday. |
fool.com |
2025-05-09 21:17:38 |
Czytaj oryginał (ang.) |
| Why Recursion Pharmaceuticals Stock Is Plummeting Today |
Shares of Recursion Pharmaceuticals (RXRX -11.15%) are tumbling on Tuesday. The stock lost 10.3% as of 2:50 p.m. |
fool.com |
2025-05-06 19:09:45 |
Czytaj oryginał (ang.) |
| RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates |
Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of certain key pipeline programs. |
zacks.com |
2025-05-06 14:20:38 |
Czytaj oryginał (ang.) |
| Recursion to Participate in Upcoming Investor Conferences |
Salt Lake City, May 06, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Bank of America 2025 Health Care Conference — Tuesday, May 13, 2025 JP Morgan Global Technology, Media and Communications Conference — Thursday, May 15, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. |
globenewswire.com |
2025-05-06 12:00:00 |
Czytaj oryginał (ang.) |
| Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday |
Recursion Pharmaceuticals (RXRX -15.53%) didn't have a fine start to the working week on Monday, at least as far as its stock was concerned. Investors traded out of it following the clinical-stage biotech's first-quarter earnings release and business update, and the share price was down by 15% in mid-session trading. |
fool.com |
2025-05-05 19:02:24 |
Czytaj oryginał (ang.) |
| Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript |
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q1 2025 Results Conference Call May 5, 2025 8:00 AM ET Company Participants Chris Gibson - Co-Founder & Chief Executive Officer Najat Khan - Chief R&D Officer and Chief Commercial Officer Ben Taylor - Chief Financial Officer Chris Gibson Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, and I'm delighted to welcome you to our Earnings Call this morning. |
seekingalpha.com |
2025-05-05 17:37:02 |
Czytaj oryginał (ang.) |
| Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates |
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago. |
zacks.com |
2025-05-05 12:15:33 |
Czytaj oryginał (ang.) |
| Recursion Reports First Quarter 2025 Financial Results and Provides Business Update |
SALT LAKE CITY, May 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-05 10:00:00 |
Czytaj oryginał (ang.) |
| Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings |
AI is revolutionizing healthcare, with Recursion Pharmaceuticals leveraging AI and vast datasets for drug discovery, making it a compelling investment opportunity. Recursion's integrated drug discovery platform, partnerships with major pharma companies, and significant data resources, position it for growth despite current financial challenges. The FDA's shift towards AI-based models for preclinical drug development could provide Recursion with a strong tailwind, reducing costs and accelerating timelines. |
seekingalpha.com |
2025-05-05 08:02:01 |
Czytaj oryginał (ang.) |
| Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden |
SALT LAKE CITY, May 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical-stage TechBio company decoding biology to radically improve lives, today announced preliminary safety and efficacy results from its ongoing Phase 1b/2 TUPELO trial of REC-4881, an investigational, allosteric MEK1/2 inhibitor in development for Familial Adenomatous Polyposis (FAP). These data were presented in a late-breaking oral presentation at Digestive Disease Week (DDW) 2025 in San Diego, California. |
globenewswire.com |
2025-05-04 16:45:00 |
Czytaj oryginał (ang.) |
| Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing |
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $5.84, denoting a +1.83% change from the preceding trading day. |
zacks.com |
2025-04-28 22:55:41 |
Czytaj oryginał (ang.) |
| Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th |
Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT |
globenewswire.com |
2025-04-28 12:27:00 |
Czytaj oryginał (ang.) |
| 3 Monster Stocks to Hold for the Next 10 Years |
Got a little money and a lot of time? Say, 10 years or more? |
fool.com |
2025-04-23 13:45:00 |
Czytaj oryginał (ang.) |
| Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 |
Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data during the 2025 Digestive Disease Week (DDW) meeting from its ongoing Phase 1b/2 clinical trial, TUPELO, which is evaluating the safety and preliminary activity of REC-4881 for the treatment of familial adenomatous polyposis (FAP). The data will be presented as a late-breaking oral presentation during the Research Forum session on Hereditary GI cancer syndromes on Sunday, May 4, 2025 in San Diego. |
globenewswire.com |
2025-04-23 00:34:00 |
Czytaj oryginał (ang.) |
| Investment strategist picks 3 ‘new age' healthcare stocks to buy |
Investment strategist Shay Boloor has highlighted three companies driving the “new age” of healthcare, making them must-watch opportunities for investors. |
finbold.com |
2025-04-20 10:42:15 |
Czytaj oryginał (ang.) |
| This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy? |
Artificial intelligence (AI) is taking over the world. Individuals and corporations are implementing the technology in their day-to-day lives and operations; governmental institutions are doing the same. |
fool.com |
2025-04-18 13:00:00 |
Czytaj oryginał (ang.) |
| HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data |
PHILADELPHIA , April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, has licensed its real-world data to enhance clinical trial design and analytics. Through this agreement, Recursion will integrate HealthVerity de-identified data for over 340M covered lives within the US into its advanced data science and machine learning platforms, the Recursion OS, allowing for deeper insights into patient populations, enhanced trial design and feasibility assessments, as well as clinical operations workflows. |
prnewswire.com |
2025-04-16 12:30:00 |
Czytaj oryginał (ang.) |
| Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th |
Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on February 28, 2025 at 8:30 am ET / 6:30 am MT / 1:30 pm GMT. |
globenewswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite? |
Recursion Pharmaceuticals' NASDAQ: RXRX stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence (AI) chip giant NVIDIA NASDAQ: NVDA. A recent SEC filing showed NVIDIA reshuffling its AI investment portfolio, and while it trimmed its holdings in several AI ventures, it notably maintained its stake in Recursion Pharmaceuticals. |
marketbeat.com |
2025-02-21 10:03:18 |
Czytaj oryginał (ang.) |
| Altitude Lab Startups Raise $154M in Capital |
The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones |
globenewswire.com |
2025-02-18 13:00:00 |
Czytaj oryginał (ang.) |
| Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock |
RXRX is expected to provide updates on its oncology and rare disease pipeline in its fourth-quarter earnings release, given the absence of a marketed product. |
zacks.com |
2025-02-18 11:41:12 |
Czytaj oryginał (ang.) |
| 25 Top AI Stocks That Could Boost Your Portfolio |
The artificial intelligence (AI) revolution is reshaping the global economy at an unprecedented pace, with innovations emerging across every sector from healthcare to transportation. As companies race to integrate AI capabilities into products and services, investors are keenly searching for opportunities to capitalize on this technological transformation. |
fool.com |
2025-02-18 10:30:00 |
Czytaj oryginał (ang.) |
| Why Recursion Pharmaceuticals Stock Is Soaring Today |
Shares of Recursion Pharmaceuticals (RXRX 16.12%) had soared by 15.8% as of 12:06 p.m. ET on Friday. |
fool.com |
2025-02-14 14:07:40 |
Czytaj oryginał (ang.) |
| Biotechs on the Brink: 2 Stocks With Huge Potential |
Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to keep their doors open during a pre-revenue period while they develop drug treatments and other medical products, but the process can be slow and, for those on the outside, opaque. Then, if all goes according to plan, these firms may see success in the form of promising data, successful trial results, or approval from a regulatory agency like the FDA. |
marketbeat.com |
2025-02-14 09:15:19 |
Czytaj oryginał (ang.) |
| Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why |
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $8.50, indicating a +1.92% shift from the previous trading day. |
zacks.com |
2025-02-13 20:51:24 |
Czytaj oryginał (ang.) |
| Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off |
Company is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. The company is also progressing REC-994 for Cerebral Cavernous Malformation, with phase 2 data expected to be published and FDA guidance sought for further development. The global solid tumor market is expected to reach $375.4 billion by 2034. |
seekingalpha.com |
2025-02-13 20:05:28 |
Czytaj oryginał (ang.) |
| Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar? |
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-02-13 08:21:12 |
Czytaj oryginał (ang.) |
| Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider |
Recursion Pharmaceuticals (RXRX) closed at $7.66 in the latest trading session, marking a +0.13% move from the prior day. |
zacks.com |
2025-02-11 20:56:26 |
Czytaj oryginał (ang.) |
| Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference |
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported 12 month data from the Phase 2 study (SYCAMORE) of REC-994, the first industry sponsored Phase 2 trial completed in Cerebral Cavernous Malformations (CCM). The Company announced in September 2024 that the signal-finding study met its primary endpoint . |
globenewswire.com |
2025-02-05 19:24:00 |
Czytaj oryginał (ang.) |
| Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note |
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $7.25, representing a +0.14% change from its previous close. |
zacks.com |
2025-02-03 20:56:13 |
Czytaj oryginał (ang.) |
| Cathie Wood's Top Biotech Plays for February |
Don't look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns. |
247wallst.com |
2025-02-02 21:40:23 |
Czytaj oryginał (ang.) |
| 3 Monster Stocks to Hold for the Next 10 Years |
Are you looking for high-odds, high-growth prospects to buy and hold for the next decade? That's a tall order to be sure. |
fool.com |
2025-02-01 07:45:00 |
Czytaj oryginał (ang.) |
| Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last? |
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-01-23 12:46:18 |
Czytaj oryginał (ang.) |
| 2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 |
Investors looking for stocks that could make dramatic moves in a short, defined time frame will want to turn their attention toward two innovative drugmakers. A couple of stocks in the volatile biopharmaceutical industry are poised to soar by the end of March. |
fool.com |
2025-01-21 06:29:00 |
Czytaj oryginał (ang.) |
| Is Recursion Pharmaceuticals Stock a Buy? |
Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion Pharmaceuticals (RXRX -0.31%) could be positioned to ride the ongoing wave of hype to great heights. Between its AI-first approach to designing new drugs and its positioning as a valuable collaborator for other companies, the company is worth paying attention to at a minimum. |
fool.com |
2025-01-17 07:47:00 |
Czytaj oryginał (ang.) |
| Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing |
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $6.42, marking a +1.58% move from the previous day. |
zacks.com |
2025-01-15 20:55:22 |
Czytaj oryginał (ang.) |
| Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect? |
The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-01-10 13:01:34 |
Czytaj oryginał (ang.) |
| Is Recursion Pharmaceuticals Stock a Millionaire Maker? |
Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the power of compounding to work its magic over time. |
fool.com |
2024-12-21 11:00:00 |
Czytaj oryginał (ang.) |
| 1 Artificial Intelligence (AI) Stock That Could Soar in 2025 |
The artificial intelligence (AI) field has been grabbing many headlines on Wall Street in the past two years. Will this trend continue in 2025? |
fool.com |
2024-12-21 10:25:00 |
Czytaj oryginał (ang.) |
| Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules |
Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that on December 19, 2024, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 7,952,836 shares of its class A common stock in the aggregate to 230 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with a subsidiary of Recursion in connection with Recursion's acquisition of Exscientia plc and pursuant to Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-12-20 18:05:00 |
Czytaj oryginał (ang.) |
| Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform |
Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The recent acquisition of Exscientia strengthens Recursion's pipeline and partnerships, potentially delivering up to $20 billion in milestone payments from collaborations with pharma giants. Despite unimpressive clinical trial results, the company's innovative platform and strategic partnerships justify a "Buy" rating for long-term, high-risk-tolerant investors. |
seekingalpha.com |
2024-12-12 08:07:47 |
Czytaj oryginał (ang.) |
| Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability |
SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. |
globenewswire.com |
2024-12-09 20:00:00 |
Czytaj oryginał (ang.) |
| Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245 |
Recursion Pharmaceuticals, Inc. expects to meet with the FDA to discuss the potential of advancing REC-994 for the treatment of patients with cerebral cavernous malformation. REC-1245 is a CDK12-adjacent target being developed in a phase 1/2 study for the treatment of patients with biomarker-enriched solid tumors and lymphomas. Data from the phase 1/2 study, exploring the use of REC-1245 for the treatment of patients with biomarker-enriched solid tumors/lymphomas, is expected by the end of 2025 or 1st half of 2026. |
seekingalpha.com |
2024-12-09 17:14:33 |
Czytaj oryginał (ang.) |
| NVIDIA Invested in These 2 AI Stocks, Should You? |
NVIDIA Co. NASDAQ: NVDA is the undisputed leader of the artificial intelligence (AI) revolution. The company envisioned an AI future over 12 years ago and began executing the blueprint for domination. |
marketbeat.com |
2024-12-02 10:37:04 |
Czytaj oryginał (ang.) |
| 2 Innovative Stocks That Could Deliver Outsize Returns |
2 Innovative Stocks That Could Deliver Outsize Returns |
fool.com |
2024-11-22 12:00:00 |
Czytaj oryginał (ang.) |
| Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery |
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform. Exscientia ADSs (Nasdaq: EXAI) ceased trading and will be delisted from Nasdaq. |
globenewswire.com |
2024-11-20 09:00:00 |
Czytaj oryginał (ang.) |
| Recursion and Exscientia Shareholders Approve the Proposed Combination |
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close |
globenewswire.com |
2024-11-13 11:08:00 |
Czytaj oryginał (ang.) |
| Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden |
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler |
globenewswire.com |
2024-11-12 18:54:00 |
Czytaj oryginał (ang.) |
| Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates |
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.43 per share a year ago. |
zacks.com |
2024-11-06 22:01:39 |
Czytaj oryginał (ang.) |
| Is Recursion Pharmaceuticals a Millionaire-Maker Stock? |
In an environment where the typical small biotech name is riskier than not, this one is curiously different. |
fool.com |
2024-11-02 11:45:00 |
Czytaj oryginał (ang.) |
| Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider |
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $6.40, representing a +1.27% change from its previous close. |
zacks.com |
2024-11-01 20:50:58 |
Czytaj oryginał (ang.) |
| Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know |
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.68, signifying a -0.89% move from its prior day's close. |
zacks.com |
2024-10-30 20:56:33 |
Czytaj oryginał (ang.) |
| Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th |
Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia |
globenewswire.com |
2024-10-30 10:22:00 |
Czytaj oryginał (ang.) |
| 3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock |
This company stands to benefit from a shifting pharmaceutical industry landscape. |
fool.com |
2024-10-26 13:00:00 |
Czytaj oryginał (ang.) |
| Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know |
Recursion Pharmaceuticals (RXRX) reachead $6.36 at the closing of the latest trading day, reflecting a +0.47% change compared to its last close. |
zacks.com |
2024-10-24 22:56:17 |
Czytaj oryginał (ang.) |
| Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection |
SALT LAKE CITY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral small molecule and new chemical entity for the treatment of recurrent Clostridioides difficile infection. C. diff is a toxin producing bacteria that causes diarrhea and colitis, and can be life threatening. Up to 730,000 cases are estimated to occur in the U.S. and EU5 annually, and the infection is responsible for an estimated 29,000 deaths in the U.S. each year. Recursion's study will initially address the recurrent C. diff. (up to 175,000 cases in the United States per year) population, which costs the healthcare system approximately two billion dollars per year . |
globenewswire.com |
2024-10-22 12:00:00 |
Czytaj oryginał (ang.) |
| Prediction: These 2 Stocks Could Soar in 2025 |
The key word here is "could." |
fool.com |
2024-10-17 13:45:00 |
Czytaj oryginał (ang.) |